BEAT BioTherapeutics

BEATBio Therapeutics announces publication of their milestone paper in the European Journal of Heart failure - BB-R12 Provides Significant Improvement in Cardiac Function in Heart Failure Study -also published in Business Wire June 4, 2025

BEAT BioTherapeutics announces founder Mike Regnier to present new data supporting the effectiveness of BB-R12 in treating heart failure at the American Society for Gene and Cell Therapy annual meeting May, 2, 2015

BEAT BioTherapeutics announces dATP technology improves cardiac function in end stage human heart failure cardiac muscle. Results published in the Journal of Molecular and Cellular Cardiology Jan 7, 2025

BEAT BioTherapeutics Announces Scientific Presentations of Promising New Heart Failure Treatment at the American Heart Association Meeting November 14, 2025

BEAT BioTherapeutic’s co-founder, Dr. Michael Regnier, to present at International Society for Heart Research Meeting May 12, 2025

BEAT BioTherapeutics appoints Dr. Sam L. Teichman as Chief Medical Officer March 14, 2025

BEAT BioTherapeutic’s co-founder, Dr. Michael Regnier, to present at American College of Cardiology Annual Meeting March 27, 2025

BEAT BioTherapeutics Corporation closes $2.5MM Seed Financing to develop its gene therapy treatment for heart failure April 15th, 2013

BEAT BioTherapeutics Corporation appoints Michael Kranda as CEO April 15th, 2013

Gene therapy may aid failing hearts – UW Medicine article, March 26, 2025

UW Researchers see work as step toward regenerating human heart – Seattle Times article, Aug 7, 2025

Papers and Publications:

Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure

• Shin Kadota, John Carey, Hans Reinecke, James Leggett, Sam Teichman, Michael A. Laflamme, Charles E. Murry, Michael Regnier, and Gregory G. Mahairas European Journal of Heart European Journal of Heart Failure (2015) doi:10.1002/ejhf.270Failure (2015)

2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure

• Farid Moussavi-Harami, Maria V. Razumova, Alice W. Racca, Yuanhua Cheng, April Stempien-Otero, Michael Regnier. Moussavi-Harami et al. / Journal of Molecular and Cellular Cardiology 79 (2015) 256–263

Up regulation of cardiomyocyte ribonucleotide reductase increases intracellular 2 deoxy-ATP, contractility, and relaxation

• Korte FS, Dai J, Buckley K, Feest ER, Adamek N, Geeves MA, Murry CE, Regnier M. J Mol Cell Cardiol. 2011 Dec;51(6):894-901

Transgenic overexpression of ribonucleotide reductase improves cardic performance.

• Nowakowski SG, Kolwicz SC, Korte FS, Luo Z, Robinson-Hamm JN, Page JL, Brozovich F, Weiss RS, Tian R, Murry CE, Regnier M. Proc Natl Acad Sci U S A. 2013 Mar 25

Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts.

• Shiba Y, Fernandes S, Zhu WZ, Filice D, Muskheli V, Kim J, Palpant NJ, Gantz J, Moyes KW, Reinecke H, Van Biber B, Dardas T, Mignone JL, Izawa A, Hanna R, Viswanathan M, Gold JD, Kotlikoff MI, Sarvazyan N, Kay MW, Murry CE, Laflamme MA.Nature 2012 Sep13 489(7415):322-5.

Refueling the heart: Using 2-deoxy-ATP to enhance cardiac contractility. Baker AJ.

• J Mol Cell Cardiol. 2011 Dec;51(6):883-4.

Enhanced contractility with 2-deoxy-ATP and EMD 57033 is correlated with reduced myofibril structure and twitch power in neonatal cardiomyocytes.

• Rodriguez AG, Rodriguez ML, Han SJ, Sniadecki NJ, Regnier M.
• Integr Biol (Camb). 2013 Nov;5(11):1366-73. doi: 10.1039/c3ib40135a. Epub 2013 Sep 10.

Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells.

• Lundy SD, Zhu WZ, Regnier M, Laflamme MA.
• Stem Cells Dev. 2013 Jul 15;22(14):1991-2002. doi: 10.1089/scd.2012.0490. Epub 2013 Apr 5

Enhanced Ca2+ binding of cardiac troponin reduces sarcomere length dependence of contractile activation independently of strong crossbridges.

• Korte FS, Feest ER, Razumova MV, Tu AY, Regnier M.
• Am J Physiol Heart Circ Physiol. 2012 Oct 1;303(7):H863-70. doi: 10.1152/ajpheart.00395.2012. Epub 2012 Aug 3.

Structural and functional consequences of the cardiac troponin C L48Q Ca(2+)-sensitizing mutation.

• Wang D, Robertson IM, Li MX, McCully ME, Crane ML, Luo Z, Tu AY, Daggett V, Sykes BD, Regnier M.
• Biochemistry. 2012 Jun 5;51(22):4473-87. Epub 2012 May 23.

2-deoxy-ATP enhances contractility of rat cardiac muscle.

• Regnier M, Rivera AJ, Chen Y, Chase PB.
• Circ Res. 2000 Jun 23;86(12):1211-7.

The effect of ATP analogs on posthydrolytic and force development steps in skinned skeletal muscle fibers.

• Regnier M, Homsher E.
• Biophys J. 1998 Jun;74(6):3059-71.

ATP analogs and muscle contraction: mechanics and kinetics of nucleoside triphosphate binding and hydrolysis.

• Regnier M, Lee DM, Homsher E.
• Biophys J. 1998 Jun;74(6):3044-58.

Calcium regulation of tension redevelopment kinetics with 2-deoxy-ATP or low [ATP] in rabbit skeletal muscle.

• Regnier M, Martyn DA, Chase PB.
• Biophys J. 1998 Apr;74(4):2005-15.